Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Receives marketing clearance Dec. 16 for ibuprofen oral suspension 40 mg/mL concentrated drops (ANDA 75-217). The product is equivalent to McNeil Consumer Products' Children's Motrin Concentrated Drops, for which patent exclusivity expired Dec. 16. Exclusivity for the NDAed drug originally was set to expire June 16, but McNeil gained an extra six months of exclusivity under a FDAMA provision that allows extra sole marketing time for studies in pediatric populations. Perrigo and Alpharma have a joint licensing agreement to market, sell and distribute children's oral ibuprofen suspension in the U.S
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning